Great Lakes Advisors LLC Reduces Stock Position in Elanco Animal Health Incorporated $ELAN

Key Points

• Great Lakes Advisors LLC reduced its stake in Elanco Animal Health by 4.1%, owning approximately 973,234 shares valued at $10.2 million after selling 41,804 shares.
• Elanco's recent financial results showed earnings per share of $0.26, surpassing estimates and reflecting a 4.8% increase in quarterly revenue year-over-year.
• Several analysts have raised their price targets for Elanco, with UBS Group setting a new target of $19.00, while overall analyst consensus is a "Moderate Buy" rating with an average target price of $17.33.

Great Lakes Advisors LLC trimmed its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 4.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 973,234 shares of the company's stock after selling 41,804 shares during the period. Great Lakes Advisors LLC owned approximately 0.20% of Elanco Animal Health worth $10,219,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Yousif Capital Management LLC bought a new stake in Elanco Animal Health in the 1st quarter valued at about $119,000. Wealth Enhancement Advisory Services LLC bought a new stake in Elanco Animal Health during the 1st quarter worth approximately $111,000. SG Americas Securities LLC bought a new stake in Elanco Animal Health during the 1st quarter worth approximately $891,000. Comerica Bank increased its holdings in Elanco Animal Health by 46.4% during the 1st quarter. Comerica Bank now owns 49,680 shares of the company's stock worth $522,000 after purchasing an additional 15,754 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in Elanco Animal Health by 1,743.8% during the 1st quarter. GAMMA Investing LLC now owns 12,390 shares of the company's stock worth $130,000 after purchasing an additional 11,718 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on ELAN shares. Leerink Partnrs raised Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 17th. Wall Street Zen raised Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Zacks Research downgraded Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 20th. Leerink Partners upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price objective on the stock in a research note on Thursday, July 17th. Finally, Stifel Nicolaus increased their target price on Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.33.

Elanco Animal Health Trading Down 1.4%

Shares of NYSE:ELAN traded down $0.26 on Friday, reaching $18.52. 5,246,037 shares of the company traded hands, compared to its average volume of 9,991,873. The business's 50-day simple moving average is $16.37 and its 200 day simple moving average is $13.21. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $19.08. The stock has a market capitalization of $9.20 billion, a P/E ratio of 21.53, a price-to-earnings-growth ratio of 3.44 and a beta of 1.62. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.20 by $0.06. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The firm had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $1.19 billion. During the same period last year, the firm earned $0.30 earnings per share. The company's revenue for the quarter was up 4.8% compared to the same quarter last year. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.